Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 370 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
Md. Akil Hossain,Rokeya Pervin
2The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Řrgaard,Jens J. Holst
3Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study
Ayman A Al Hayek,Asirvatham A Robert,Mohamed A Al Dawish
Clinical Medicine Insights: Endocrinology and Diabetes.2019;12(9)117955141983493
4GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito,Otávio Berwanger,Luiz Sérgio F. de Carvalho,José Francisco Kerr Saraiva
Cardiovascular Diabetology.2018;17(1)117955141983493
5Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Leigh Perreault,Helena Rodbard,Virginia Valentine,Eric Johnson
Advances in Therapy.2019;36(2)265
6Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Juergen Sandow
Advances in Therapy.2020;36(2)1
7A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
Neil Webb,Michelle Orme,Michal Witkowski,Rie Nakanishi,Jakob Langer
Diabetes Therapy.2018;9(3)973
8Effect of semaglutide on coronary atherosclerosis progression in patients with type II diabetes
Sajad Hamal,Lavanya Cherukuri,Kashif Shaikh,April Kinninger,Jay Doshi,Divya Birudaraju,Matthew J. Budoff
Coronary Artery Disease.2020;31(3)306
9Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock,Christopher H. Sorli,Michael E. Trautmann,Cristóbal Morales,Ulrich Wendisch,George Dailey,Marcus Hompesch,In Young Choi,Jahoon Kang,John Stewart,Kun-Ho Yoon
Diabetes Care.2019;42(9)1733
10A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera,Ana Cebrián-Cuenca,Fernando Álvarez-Guisasola,Fernando Gomez-Peralta,Jesús Reviriego
Diabetes Therapy.2019;10(1)5
11Lixisenatide: A New Option for Managing Type 2 Diabetes
Jonathan S. Newsome
Journal of Pharmacy Technology.2017;33(5)195
12Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats
Sunil Kumar,Raymond Lau,Thomas Palaia,Christopher Hall,Jenny Lee,Keneth Hall,Collin E. Brathwaite,Louis Ragolia
Annals of Medicine and Surgery.2016;12(5)65
13Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats
Dongxu Zhao,Li Ma,Chuanan Shen,Dawei Li,Wenfeng Cheng,Yuru Shang,Zhaoxing Liu,Xin Wang,Kai Yin
Journal of Burn Care & Research.2018;39(4)545
14GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
Marco Castellana,Angelo Cignarelli,Francesco Brescia,Luigi Laviola,Francesco Giorgino
Diabetes/Metabolism Research and Reviews.2019;35(1)e3082
15Narrative review of the effects of antidiabetic drugs on albuminuria
Habib Yaribeygi,Stephen L. Atkin,Niki Katsiki,Amirhossein Sahebkar
Journal of Cellular Physiology.2019;234(5)5786
16Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Sanjay Kalra,Ashok Kumar Das,Rakesh Kumar Sahay,Manash Pratim Baruah,Mangesh Tiwaskar,Sambit Das,Sudip Chatterjee,Banshi Saboo,Ganapathi Bantwal,Saptarshi Bhattacharya,Gagan Priya,Manoj Chawla,Kiraninder Brar,Syed Abbas Raza,Azizul Hasan Aamir,Dina Shrestha,Noel Somasundaram,Prasad Katulanda,Faria Afsana,Shahjada Selim,Mohammad Wali Naseri,Ali Latheef,Manilka Sumanatilleke
Diabetes Therapy.2019;10(5)1645
17Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
Lima Lawrence,Venu Menon,Sangeeta Kashyap
Current Cardiology Reports.2018;20(8)1645
18Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
Dongzhe Hong,Lei Si,Minghuan Jiang,Hui Shao,Wai-kit Ming,Yingnan Zhao,Yan Li,Lizheng Shi
19Safety and efficacy of antihyperglycaemic agents in diabetic kidney disease
Sebastian Niezen,Humberto Diaz del Castillo,Lumen A. Mendez Castaner,Alessia Fornoni
Endocrinology, Diabetes & Metabolism.2019;20(8)e00072
20Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
Marco Castellana,Angelo Cignarelli,Francesco Brescia,Sebastio Perrini,Annalisa Natalicchio,Luigi Laviola,Francesco Giorgino
Scientific Reports.2019;9(1)e00072
21The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy.2017;34(3)638
22Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy
Philip D. Home,Bo Ahrén,Jane E.B. Reusch,Marc Rendell,Peter N. Weissman,Deborah T. Cirkel,Diane Miller,Philip Ambery,Molly C. Carr,Michael A. Nauck
Diabetes Research and Clinical Practice.2017;131(3)49
23Body Weight Considerations in the Management of Type 2 Diabetes
Caroline M. Apovian,Jennifer Okemah,Patrick M. O’Neil
Advances in Therapy.2019;36(1)44
24Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Ying Liu,Xia Jiang,Xin Chen
Lipids in Health and Disease.2017;16(1)44
25GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
Roy Rasalam,John Barlow,Mark Kennedy,Pat Phillips,Alan Wright
Diabetes Therapy.2019;10(4)1205
26Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)
Shengwu Ma,Liang We,Hongji Yang,Shaoping Deng,Anthony M. Jevnikar
Canadian Journal of Biotechnology.2017;1(1)1
27Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M.S. Capehorn,A.-M. Catarig,J.K. Furberg,A. Janez,H.C. Price,S. Tadayon,B. Vergčs,M. Marre
Diabetes & Metabolism.2020;46(2)100
28The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Carlota Recio,Francesco Maione,Asif J. Iqbal,Nicola Mascolo,Vincenzo De Feo
Frontiers in Pharmacology.2017;7(2)100

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal